An appendectomy costs $22,500 in the US and $1,800 in India. Insulin lists for ten times more in America than in France. An audit of eight systems.
The Price Catalog
Same Procedure, Eight Prices
A coronary bypass is the same operation — open chest, harvest a vein, graft around a blocked artery — in Houston, Bangkok, Berlin, or Bangalore. ✓ Established The price is not the same. The differential is not 10% or 50%; it is, in the cardiac case, a factor of sixteen between the cheapest and most expensive accredited venue [11].
Health spending separates the United States from every other wealthy democracy by a structural margin. In 2024 the country spent $14,885 per capita on health — more than twice the OECD average of roughly $6,500, and well above the next-highest spender, Switzerland [1]. That spending equates to 17.2% of US gross domestic product, against an OECD mean of 11.2%. Germany follows at 12.7%, France at 11.9%, Japan at 11.5%, the United Kingdom at 11.3% ✓ Established. The headline numbers are not in dispute. What the numbers buy, however, varies by country in ways that have no plausible medical explanation.
Consider an appendectomy — the textbook example of a routine emergency operation. In the United States the average price is approximately $22,500 [2]. In Germany, where surgical training, technology, and outcome standards are demonstrably comparable, the same procedure runs $8,500–$13,500 — a saving of roughly 51% ◈ Strong Evidence. In the United Kingdom an NHS appendectomy is invoiced internally at about $8,009; in private Indian hospitals the price falls below $2,000 [11]. The appendix is not in any sense different across continents. The institutions that remove it are.
Drug pricing magnifies the spread. Insulin — discovered in 1921, patented for $1 by Frederick Banting and his collaborators, and continuously refined since — costs an average of $99 per unit in the United States. The same insulin, produced by the same multinational manufacturers and shipped from the same plants, costs $11 in Germany, $9 in France, $14 in Japan, and $12 in Canada [3]. The ratio between the most expensive and cheapest large markets exceeds tenfold ✓ Established Fact.
Ozempic, the GLP-1 agonist whose 2024–2025 demand surge has reshaped diabetes and obesity treatment, follows the same pattern with greater extremity. The monthly US list price is $936; the French price is $83 [5]. Across the top five European markets, daily costs run 183% to 267% lower than the American equivalent ✓ Established. Wegovy, the higher-dose semaglutide formulation marketed for weight loss, shows comparable divergence.
Childbirth illustrates the same pattern through an entirely different procedural pathway. The average cost of pregnancy and delivery in the United States now totals $20,416, with out-of-pocket exposure of $2,743 for patients enrolled in employer-sponsored plans [4]. The median vaginal delivery alone runs $8,655 — the highest of any OECD country. In Germany the equivalent cost ranges $4,100–$4,900. In France, maternal care is reimbursed at 100% by social security from the first prenatal visit through postpartum care ◈ Strong Evidence. A French mother and an American mother are not delivering different babies. They are delivering them in different price regimes.
The simplest framing of the comparison is to ask what a benchmark dollar amount buys. One thousand dollars covers, in the United States, perhaps a single emergency-room visit for a non-life-threatening complaint, with the bill regularly settling between $1,500 and $3,000 for uninsured patients [2]. In Thailand the same sum funds a complete dental restoration, including implants and prosthetics. In India it underwrites a full cardiac workup, including echocardiogram, angiography, and consultation, at Apollo Hospital. In France it represents roughly the entire annual out-of-pocket exposure for an average household after public reimbursement.
The same money does not buy the same medicine because the institutional context — who negotiates, who pays, who bears risk — differs at every stage. The remainder of this report traces those differences across eight national systems and assesses what the data implies for the patient, the taxpayer, and the regulator.
Three Architectures, Eight Systems
A Taxonomy of Health Finance
Despite eight national variations, modern health systems descend from three architectural choices made between 1883 and 1961: the Bismarck model of mandatory social insurance, the Beveridge model of tax-funded national service, and the residual model of market provision with selective public subsidy [1].
The first architecture — what economists now call the Bismarck model — emerged from German chancellor Otto von Bismarck's 1883 Sickness Insurance Law, which compelled industrial employers to fund medical care for low-wage workers through "sick funds" jointly administered by employers and employees ✓ Established. The model spread across continental Europe through the late nineteenth and early twentieth centuries; Japan adopted a Bismarck-style universal insurance system in 1961. Today, Germany, France, Japan, and the Netherlands operate under variants of this template. Coverage is mandatory, financing is payroll-based and supplemented by general taxation, and providers are predominantly private but tightly regulated.
The second architecture — the Beveridge model — appeared in 1948 with the United Kingdom's National Health Service, the first modern system to deliver universal coverage as a tax-funded public service free at the point of use [7]. The NHS combines public financing, public ownership of hospitals, and public employment of clinical staff. Sweden, Denmark, Spain, Italy, and Canada have adopted variants. The distinguishing feature is not universality — which Bismarck systems also achieve — but the unified public character of financing and provision.
The third architecture is the residual model, exemplified by the United States. Coverage is fragmented across employer-sponsored insurance, Medicare for those over 65, Medicaid for low-income populations, the Veterans Health Administration, the Indian Health Service, the Affordable Care Act marketplaces, and an uninsured population that fluctuates with the political cycle [8]. No single entity negotiates prices on behalf of the whole population, and no statutory entitlement to coverage exists outside the elderly, the very poor, and qualifying veterans. The model is residual in the sense that public provision fills only the gaps left after private market activity.
OECD comparative price studies consistently identify monopsony purchasing power — a single payer or a tightly coordinated set of payers facing competing providers — as the primary structural determinant of low prices. The same insulin pen, manufactured in the same factory, costs $99 in the United States and $9 in France because the French Caisse Nationale d'Assurance Maladie negotiates as a national monopsony while US purchasers compete for the same drug in fragments [3]. Pharmaceutical innovation occurs in both jurisdictions.
The eight countries assessed in this report distribute across the three architectures unevenly. Germany, France, and Japan operate mature Bismarck systems with universal coverage funded primarily through social insurance contributions. The United Kingdom remains the canonical Beveridge system, though its 2025 deficit and waiting-list crisis have intensified debate about the model's resilience under chronic underfunding [7]. The United States is the only high-income holdout from universality. India, Brazil, and Thailand occupy mixed positions: each has built a public universal-coverage layer (Ayushman Bharat in India, SUS in Brazil, UCS in Thailand), atop which a substantial private sector serves both domestic middle-class patients and international medical tourists [13].
The implication for the price catalogue surveyed above is precise. The countries with the lowest prices for both drugs and procedures are those whose architectures concentrate purchasing power: France, the United Kingdom, Japan, and Germany. The countries with the highest prices are those whose architectures fragment it: the United States in particular, where roughly 1,500 distinct insurance entities negotiate against an even larger universe of providers, each contract bespoke. Thailand and India achieve low prices through a different route — low domestic labour and overhead costs combined with state-driven volume contracting — but the principle holds: where purchasing power is consolidated, prices fall.
Brazil's hybrid demonstrates the tension explicitly. The Sistema Único de Saúde, established by the 1988 constitution, funds 45% of national health spending and provides universal access in principle [13] ◈ Strong Evidence. Out-of-pocket payments constitute 27.4% of spending, and prepaid private plans another 27.5%. The middle class purchases supplementary cover; the poor depend on the public layer; and the result is two-tier access despite a constitutional commitment to equity.
Thailand's Universal Coverage Scheme, launched in 2002 under the "30-baht treatment scheme" branding, provides essentially universal coverage at roughly 4% of GDP — one of the most efficient systems in the world. The country has paired the public layer with an explicitly export-oriented private sector that draws international medical tourists. The country's positioning of high-quality, low-priced procedures has made Bumrungrad and Bangkok Hospital household names among Asian and Middle Eastern patients [10].
Architecture, not biology, is the variable that moves prices. The remainder of the report quantifies the consequences.
The Drug Pricing Gap
Insulin, Ozempic, Humira
The same drug — same molecule, same packaging, frequently the same manufacturing line — sells for radically different prices across borders [3]. The differential is not explained by R&D recovery, since the gap persists for generics and biosimilars where original patents have long expired.
Insulin is the cleanest case because its century-long history removes any plausible patent-amortisation defence. Frederick Banting and Charles Best transferred their 1921 discovery to the University of Toronto for a token $1 each, intending to prevent monopolisation. By 2024, three multinationals — Novo Nordisk, Eli Lilly, and Sanofi — controlled more than 90% of the global insulin market. The US average gross price reached $99 per unit; France paid $9, Germany $11, and Japan $14 [3] ✓ Established Fact. The gap is not 10% or 20% but more than tenfold.
Adalimumab, marketed as Humira by AbbVie, illustrates the same divergence on a more expensive biologic. Two kits of Humira Pen (40 mg) cost an average of $4,480 in the United States, compared to $1,570 in Germany [3]. After biosimilar entry in Europe between 2018 and 2023, European prices fell another 30–40%. US biosimilar uptake lagged for structural reasons: the rebate-driven pharmacy benefit manager model rewards high list prices, since rebates calculated as percentages of list create stronger incentives for branded products than for cheaper biosimilars. The result is that the country with the wealthiest patient population pays the highest sticker price for a drug whose patent expired more than half a decade ago.
U.S. average gross prices were more than 10 times prices in France, about seven times prices in Germany. The pattern holds across analog and biosimilar insulins manufactured by the same companies in the same plants.
— RAND Corporation, Comparing Insulin Prices in the U.S. to Other Countries, 2024Semaglutide — Ozempic and Wegovy — is the contemporary headline drug. Demand for GLP-1 agonists for both diabetes management and weight loss has reshaped American pharmaceutical revenue projections through 2030. The US monthly list price for Ozempic stands at $936; the French equivalent is $83 [5] ✓ Established. At its European launch the daily cost in France ($4.56) ran 18% of the American daily equivalent ($25.42). Across the top five European markets, Ozempic's daily cost ranged between 183% and 267% lower than US pricing.
The R&D-recovery defence — that high US prices fund pharmaceutical innovation enjoyed worldwide — is empirically partial at best. PhRMA member companies invested approximately $104 billion in R&D in 2024, representing about 21% of their combined global revenues ◈ Strong Evidence. The Inflation Reduction Act's Medicare drug price negotiation, which industry warned would devastate research investment, did not produce the predicted retrenchment: pharmaceutical R&D spending in fact rose between Q3 2022 and 2025, reaching new highs [14]. The simpler explanation for the price gap is that European and Japanese national payers exercise countervailing market power that American fragmented payers do not.
The Centers for Medicare and Medicaid Services announced negotiated prices on the first ten Part D drugs in August 2024, with a minimum 38% discount off the 2023 list price and savings of approximately $6 billion to the Medicare programme annually plus $1.5 billion to beneficiaries [14]. The second round, naming 15 additional drugs including Ozempic and Wegovy, was announced in January 2025 with negotiated prices effective January 2027. Once fully implemented, the 25-drug programme is projected to save the federal government $13 billion per year at an average 52% discount versus prior pricing.
The contrast with peer-country price formation is structural. France's Comité Économique des Produits de Santé negotiates drug prices on behalf of the national insurance system using comparator effectiveness, budget impact, and international reference pricing. Germany's Gemeinsamer Bundesausschuss conducts benefit assessments through the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), which translates therapeutic benefit into a price ceiling. Japan's Chuikyo conducts biennial price revisions, automatically cutting prices that exceed cost-plus formulas. In each case a single national entity negotiates against pharmaceutical firms whose alternative — withdrawal — is rarely attractive [1].
For the patient the consequence is direct. In a Pew survey, 30% of US adults reported skipping prescribed medication or splitting pills because of cost; the equivalent figure in Germany was below 5%. Insulin rationing, with its documented mortality, remains a recognised category of preventable death in American clinical literature. No comparable phenomenon exists at scale in France, Germany, or Japan [8] ◈ Strong Evidence.
The drug pricing gap is not a curiosity of comparative health economics. It is the most cleanly identifiable transfer in the modern global economy: American patients funding the global pharmaceutical R&D footprint, with the rest of the OECD free-riding on negotiated prices the United States declines to demand. Whether that arrangement should continue is a political question; that it exists is not in dispute.
The Out-of-Pocket Wall
Bankruptcy in America, Poverty in India
Two countries on opposite ends of the income distribution share an unusual feature: both produce mass medical impoverishment, but through different mechanisms [9] [15]. The United States bankrupts the insured through deductibles and surprise billing; India pushes the uninsured into poverty through catastrophic out-of-pocket spending.
In the United States, approximately 100 million adults carry medical debt [9]. Medical bills constitute 58% of all debt in collections, and 62% of personal bankruptcies are attributed in part to healthcare costs ✓ Established Fact. The figure is the more striking because 92% of the population has some form of health insurance. Bankruptcy in America is not a problem of the uninsured alone; it is a problem of insurance design.
The mechanism is the deductible. The average annual deductible for an employer-sponsored single coverage plan now exceeds $1,800; family deductibles routinely exceed $4,000. High-deductible health plans, which the Affordable Care Act and the 2003 Medicare Modernization Act actively encouraged, now cover roughly 30% of insured workers. The Commonwealth Fund classifies 23% of insured working-age adults as underinsured — that is, holding coverage that nonetheless leaves them exposed to costs they cannot reasonably bear [8] ✓ Established. Adding the 28 million uninsured to the 56 million underinsured produces a functionally inadequate-coverage population of roughly 84 million Americans.
The 2022 No Surprises Act prohibited out-of-network billing for emergency care and certain non-emergency services at in-network facilities. Yet investigative reporting through 2024–2025 has documented continued surprise billing through ambiguous billing categories, ground ambulance carve-outs (excluded from the Act), and aggressive disputed-claim arbitration. Patients still face $5,000–$50,000 surprise bills despite the statute, with the No Surprises Act's effects most pronounced for emergency physician charges in JCAHO-accredited hospitals but weakest for ancillary services and ground ambulances.
The Indian mechanism operates further upstream. India spent 39.4% of total health expenditure out-of-pocket in 2021–22 — down from 64.2% in 2013–14, an improvement traceable to the 2018 launch of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), the world's largest health-insurance scheme [15] ✓ Established. Yet the residual out-of-pocket exposure remains the highest in any large economy. Forty-nine per cent of households seeking hospitalisation or outpatient care experience catastrophic health expenditure — defined as health spending exceeding 10% of household consumption — and 15% of households fall below the national poverty line as a direct result ◈ Strong Evidence.
The Indian arithmetic compounds across the rural-urban gradient. Sixty-eight per cent of rural healthcare expenditure and 58% of urban spending is out-of-pocket. PMJAY beneficiaries — those formally enrolled in the scheme — face zero out-of-pocket costs on covered surgeries; the Karnataka tertiary-hospital study found uninsured cardiac patients carrying median out-of-pocket expenditure of ₹115,292–₹172,490 ($1,390–$2,080) [12]. Approximately 32–39 million Indians cross the poverty line each year because of medical costs alone.
The Commonwealth Fund's 2024 Biennial Health Insurance Survey counts 28 million uninsured Americans plus 23% of the insured working-age population — roughly 56 million additional adults — meeting the underinsured threshold [8]. Fifty-seven per cent of underinsured respondents and 70% of recently uninsured respondents report having skipped necessary services, prescriptions, or follow-up care because of cost. The combined inadequate-coverage population approaches 84 million.
The Brazilian middle ground falls between the two extremes. Brazil's SUS provides universal access in principle, and out-of-pocket spending has declined to 27.4% of total health expenditure [13]. Yet rationing through wait times, geographic distribution of specialists, and the persistent two-tier nature of the system means that those who can afford prepaid private cover routinely take it. Twenty-seven per cent of Brazilians hold supplementary private insurance, of whom the wealthier portion access a parallel private medical economy.
By contrast, France, Germany, the United Kingdom, and Japan each cap out-of-pocket exposure through a combination of statutory ceilings, supplementary social insurance, and universal first-dollar coverage for catastrophic episodes. France's Affection de Longue Durée scheme reimburses 100% of costs for designated chronic conditions including cancer, diabetes, and HIV. Japan's High-Cost Medical Care Benefit System caps monthly out-of-pocket at roughly ¥80,000 ($550) for working-age adults. Germany's social health insurance limits annual co-pays to 2% of income (1% for chronic illness). The United Kingdom's NHS, despite its 2025 funding crisis, retains free-at-point-of-use access for all clinically necessary care [1].
The pattern is consistent. Where a national entity has been given an obligation to ensure access to care without bankrupting the patient, bankruptcy and impoverishment fall sharply. Where the obligation is dispersed across employers, insurers, hospitals, and patients themselves, the bottom percentile bears the residual.
Country Profiles
How Each System Pays the Doctor
Eight national systems, eight different settlements between patients, payers, and providers. Each architecture is the product of a specific political moment and the path-dependencies that followed [1].
United States. Per capita spending $14,885 in 2024, the highest in the world [1]. Coverage is fragmented across employer-sponsored insurance (49% of population), Medicare for seniors (15%), Medicaid for low-income (21%), the marketplaces (4%), and 8% uninsured [8]. Medicare drug price negotiation, effective for ten drugs in 2026 and fifteen more in 2027, represents the first systematic federal monopsony intervention since the programme's creation in 1965 [14]. Outcomes lag peer countries on life expectancy (78.4 years versus OECD 81+), infant mortality, and maternal mortality (a US metric that has worsened in real terms since 2000).
France. Bismarck-derived statutory health insurance covers 100% of residents, funded by employer-employee payroll contributions, general taxation, and a small co-payment system. The Sécurité Sociale reimburses approximately 80% of costs at the standard rate; supplementary mutuelles cover most of the remainder. Total spending runs 11.9% of GDP. Drug prices are negotiated centrally; insulin lists at $9 per unit and Ozempic at $83 monthly [5]. France records life expectancy of 82.6 years, one of the highest in the OECD [1]. The cost of maternal care is reimbursed in full; out-of-pocket spending averages 9% of total health expenditure.
Germany. Statutory Health Insurance (SHI) covers approximately 88% of residents through 96 sickness funds; the remaining 12% — high earners and self-employed — opt into private insurance. Total spending 12.7% of GDP. Provider rates and drug prices are negotiated at the federal level through the Gemeinsamer Bundesausschuss. Childbirth in Germany costs $4,100–$4,900; an appendectomy $8,500–$13,500 [2]. Annual out-of-pocket co-pay is capped at 2% of household income. The 2025 statutory contribution rate rose to 14.6%, plus an average 2.5% supplementary rate set by individual funds.
Japan. Universal coverage since 1961 through a hybrid of Employee Health Insurance (Kenkō Hoken) and National Health Insurance (Kokumin Kenkō Hoken). Co-pay is set at 30% for working-age adults, reduced to 10% for elderly low-income [1]. Routine clinic visits cost ¥3,000–¥5,000 ($20–$35) out-of-pocket; high-cost care is capped through the High-Cost Medical Care Benefit System. Japan records the world's highest life expectancy at 84.5 years. Total spending 11.5% of GDP, against the world's longest-lived population.
United Kingdom. Tax-funded NHS provides universal access free at point of use. The system's 2025 funding crisis has produced its sharpest stress in a generation. Only 59% of patients are treated within the statutory 18-week elective standard, against a 65% target by March 2026 and the ultimate 92% standard. By July 2025 nearly 192,000 patients were waiting more than one year for elective treatment [7] ✓ Established Fact. The NHS aggregate deficit reached £172 million by mid-fiscal 2025, with a baseline £5–6 billion shortfall projected for the full year. Junior doctor industrial action has cost £3 billion in lost productivity.
India. Mixed system with public infrastructure (district hospitals, primary health centres), a substantial private hospital network, and AB-PMJAY covering 500 million low-income citizens. Out-of-pocket spending 39.4% of total [15]. Apollo Hospitals' CABG bypass at $5,000–$9,000 versus US $80,000–$120,000 reflects both low-cost labour and the volume efficiencies of high-throughput Indian specialty hospitals [11]. India is simultaneously a country of mass medical impoverishment and a global destination for medical tourism — a contradiction the system has not resolved.
Brazil. Article 196 of the 1988 Constitution declares health "a right of all and a duty of the state." SUS funds 45% of national health spending; out-of-pocket 27.4%; private prepaid 27.5% [13]. Total spending 10.7% of GDP. The system is constitutionally universal but practically two-tier: the urban middle class purchases private cover to bypass SUS wait times, while the rural poor and informal-sector workers depend on the public layer.
Thailand. Universal Coverage Scheme reaches over 99% of citizens at approximately 4% of GDP — one of the most cost-efficient universal systems globally. The country's positioning as a medical-tourism destination has created a parallel private economy. Bumrungrad International Hospital prices cardiac surgery at $15,000–$35,000 versus US $70,000–$200,000 [10]. The country attracts approximately 3.5 million medical tourists annually, generating $7.5 billion in revenue and demonstrating that high-quality care can be priced sustainably outside Western markets.
The Outcomes Mismatch
Highest Spend, Lower Life
The United States spends approximately twice the OECD average per capita on healthcare and records life expectancy below the OECD mean by more than three years [1] ✓ Established. The relationship between spending and outcomes is, at the high end, weakly correlated.
The simplest summary of comparative outcomes is the life-expectancy ranking. Japan leads at 84.5 years; France records 82.6; Germany 81.5; the United Kingdom 81.0; the United States 78.4 [1]. The American figure is 6.1 years below the Japanese — the equivalent of a US citizen losing roughly the entire span of secondary school relative to their Japanese counterpart. The American figure also fell during the 2020–2022 COVID-19 pandemic by a margin substantially larger than the falls recorded in peer countries, indicating a system less resilient to acute shocks. Recovery through 2024–2025 has been partial.
Infant mortality follows the same pattern. The United States records approximately 5.4 infant deaths per 1,000 live births; Japan 1.8; Sweden 2.1; France 3.6; Germany 3.0. The American figure is roughly three times the Japanese — an outcome that no plausible medical or biological factor explains. Maternal mortality is similarly anomalous: 17.4 maternal deaths per 100,000 live births in the United States versus 1.6 in Norway and 2.7 in Japan. The American figure has worsened in real terms since 2000, the only OECD country with that trajectory [1] ◈ Strong Evidence.
The US performs comparably to or better than European peers on five-year cancer survival rates for several major malignancies — particularly breast (90% versus European 85%) and prostate (97% versus 88%). The advantage is real and traceable to faster diagnostic imaging access for the insured and earlier-stage screening uptake. The qualification: these are five-year survival rates among those diagnosed, a measurement that flatters health systems with aggressive early detection and disadvantages those with longer-tailed diagnostic windows. The US strength is in technology-intensive treatment of acute presentations; the weakness is in the maintenance of chronic conditions, primary prevention, and equitable access.
Preventable mortality — deaths that should not occur given timely, effective care — separates the systems further. The OECD's preventable mortality indicator places the United States at 175 deaths per 100,000 versus 81 in Japan, 117 in France, and 99 in Germany [1]. Treatable mortality follows the same pattern. The American excess concentrates among working-age adults of low and middle income — populations whose access to care is most variable across the insured-underinsured-uninsured gradient.
The countries that achieve the best outcomes share two structural features. The first is universal access to primary care, which permits chronic conditions to be managed before they become acute. The second is concentrated payer power, which keeps administrative costs low and frees public funding for clinical activity. Japan's roughly 4.7% administrative cost share contrasts with the United States' 25–30% [2]. The Public Health Foundation Japan operates 1.3 administrators per physician versus the American hospital average of 10.
| Risk | Severity | Assessment |
|---|---|---|
| US administrative cost burden | 25–30% of US health spending consumed by billing and insurance-related administration. Single-payer transition estimated to save $600 billion annually. No private-sector cost discipline visible since 1990. | |
| NHS sustainability under chronic underfunding | Baseline £5–6 billion 2025–26 deficit and £19.8 billion shortfall projected by 2028–29. Industrial action persistent. Public satisfaction at 30-year low. | |
| Indian catastrophic out-of-pocket spending | 49% of hospitalised households cross catastrophic threshold. 32–39 million Indians pushed below poverty line annually by health costs despite PMJAY rollout. | |
| US drug shortage spillover | Aggressive procurement and consolidated wholesale channels create shortage cascades that propagate to lower-income countries dependent on US-supplied generic exports. | |
| Medical tourism complication risk | Post-operative complications without continuity of care produce documented mortality and morbidity, particularly in cosmetic and bariatric procedures. JCI accreditation reduces but does not eliminate the differential. |
The conventional argument that American excess spending is a price worth paying for superior care does not survive the data. American healthcare is more expensive than peer-country care, more administratively complex, and less effective at translating spending into life-years gained. The interpretation that follows is not that the United States cannot do better; it is that the system has been optimised for different outcomes than population health.
The system has been optimised for revenue generation among medical specialists, pharmaceutical manufacturers, and the insurance and pharmacy benefit manager intermediaries who profit from billing complexity. The OECD price differential and the US outcomes deficit are the same phenomenon viewed from two angles.
The Reform Debate
Negotiation, Innovation, Access
The argument that low European prices are subsidised by American patients funding global innovation is the strongest case made by the pharmaceutical industry against reform [14] ⚖ Contested. The argument is more rhetorical than empirical, but it is not vacuous and deserves direct engagement.
The structural defence runs as follows. The development of a new molecule now costs $2.23 billion on average across the major Big Pharma firms, up from $2.12 billion the year before. PhRMA's 104 member companies invested approximately $104 billion in R&D in 2024 — about 21% of their combined global revenues. American prices, the defence argues, are the only ones high enough to fund this investment. If the United States were to negotiate prices down to European levels, R&D would collapse, and the global stock of new therapies would shrink [14].
The empirical record is more complicated. Pharmaceutical R&D investment in fact rose in the period following the Inflation Reduction Act, reaching new highs in 2024 and 2025 despite industry warnings that price negotiation would devastate the pipeline [14]. European companies — Sanofi, Roche, Novartis, AstraZeneca — operate substantial R&D footprints in regulatory environments that pay far less than American prices. The geographic distribution of pharmaceutical innovation is not as American-centric as PhRMA messaging implies; Switzerland, Germany, the United Kingdom, and Denmark host significant innovative capacity.
The Reform Case
The same drug from the same manufacturer cannot rationally cost ten times more in one country than another. Negotiated prices in Europe demonstrate that pharmaceutical companies remain profitable at much lower price points.
Administrative cost reduction from consolidating American billing and insurance overhead would free resources for clinical care, expand coverage, and reduce per-capita spending without service cuts.
Japan and France record superior life expectancy and lower infant mortality at lower per-capita spending. Architecture — universal access, concentrated payer power — explains the outcome divergence, not spending alone.
No peer country produces medical bankruptcy at American rates. The mechanism is high deductibles, fragmented coverage, and surprise billing — all amenable to statutory remedy.
The Inflation Reduction Act's first ten negotiated drugs delivered average 38% discounts off list price without measurable contraction in pharmaceutical R&D investment, validating the model in real-world implementation.
The Status-Quo Case
R&D investment of $2.23 billion per approved drug requires the cash flows that only American pricing supports. European free-riding is the cost of preserving the pipeline.
The US health sector employs 22 million people and represents 17.2% of GDP. Disruptive reform threatens employment, insurance industry stability, and the ability of providers to absorb capital costs.
Universal systems ration through wait times. NHS England's 192,000-patient one-year backlog and Canada's 28.6-week median wait are not anomalies; they are how non-price rationing operates in practice.
US cancer five-year survival exceeds European averages. American specialty medicine attracts patients globally for complex cases. Reform that depresses prices risks depressing the specialty capacity those outcomes depend on.
NIH spending of $48 billion annually rests on a tax base supported by pharmaceutical industry profits. Direct price reductions risk both private and indirect public research investment.
Neither argument is entirely wrong. The reform case is correct that low-cost universal systems achieve better population health at lower spending. The status-quo case is correct that a sudden transition would carry significant disruption costs and that some part of American pricing does cross-subsidise innovation enjoyed worldwide. The dispute is about scale, sequencing, and the design of intermediate institutional steps [14].
The 2022 Inflation Reduction Act authorised Medicare to negotiate drug prices for the first time since the programme's 1965 creation. The first ten negotiated drugs took effect in January 2026 at minimum 38% discounts. The second tranche of 15 drugs — including Ozempic, Wegovy, and other GLP-1 agonists — takes effect in January 2027. The pharmaceutical industry warned of R&D collapse; the empirical record shows R&D spending rose, drug pipelines remained robust, and the federal programme is on track to save $13 billion annually at full implementation [14] ✓ Established. The natural experiment validates negotiated pricing as a tool. Whether it will be permitted to extend further is a function of US political composition, not policy efficacy.
The argument that universal coverage produces ruinous waiting lists has its own empirical complications. The NHS England 192,000-patient one-year backlog is real [7], and the Canadian 28.6-week median wait demonstrably correlates with adverse outcomes [6]. Yet France, Germany, the Netherlands, and Switzerland operate universal-coverage systems with shorter waiting times than US Medicaid patients face. The pathology of waiting lists is not universality per se; it is universality combined with chronic underfunding. Britain has chosen to fund its NHS at 11.3% of GDP — three percentage points less than Germany — and the queue is the cost of that choice.
The status-quo case rests on the proposition that no reform sequence can capture the benefits of universal access without incurring the costs of inadequate funding. The empirical evidence from a dozen national systems indicates that this is false: well-funded universal systems exist, and their populations live longer at lower per-capita expense than the United States manages to deliver. The question is whether the political coalition to construct such a system in the United States can be assembled before the costs of the current arrangement become so severe that crisis forces the change.
The shape of any plausible American reform is increasingly visible. Medicare negotiation expands incrementally year by year. The 2010 Affordable Care Act ratcheted coverage upward through marketplace subsidies. The next steps — a public option, expanded Medicare buy-in, expanded community-rating and out-of-pocket caps — sit on the policy shelf awaiting political consent. The European and Japanese systems offer not a single model but a menu of architectural choices.
What the Evidence Tells Us
Politics, Not Medicine
The biology of healthcare is approximately constant across borders. The price is not. The variation between countries reflects political settlements about who bears risk, who profits from delivery, and who the system is for [1].
The evidence assembled in this report can be reduced to a few load-bearing observations. First, the same medical service costs radically different amounts in different countries — by factors of three to sixteen for routine procedures, and by factors above ten for branded pharmaceuticals. Second, the variation correlates strongly with payer architecture: concentrated public purchasers achieve low prices; fragmented private purchasers achieve high ones [3] [11]. Third, the relationship between health spending and population health weakens sharply once spending exceeds approximately $5,000 per capita per year. Above that level, the marginal dollar produces diminishing — and in the American case, negative — returns in life expectancy.
Fourth, every wealthy democracy except the United States has resolved the question of universal access. The architectures differ — Bismarck systems, Beveridge systems, mixed systems — but the basic settlement is the same: nobody is bankrupted by routine illness, and nobody is denied life-extending treatment because they cannot pay for it. The exception is the United States, where approximately 84 million people hold inadequate coverage and where bankruptcy is the most common single financial consequence of serious illness [8] [9] ✓ Established.
Same procedure, same molecule, same surgeon's training. The price is not a property of the medicine. It is a property of the institutions that distribute the medicine.
— Synthesis of OECD comparative price data, 2025Fifth, the medical tourism industry — Bumrungrad in Thailand, Apollo in India, Anadolu in Turkey — has demonstrated that high-quality care can be priced sustainably at one-fifth to one-tenth of American levels. The cost differential is not explained primarily by lower-paid clinical staff: Bumrungrad surgeons earn competitive international salaries, and Apollo cardiac specialists are routinely Western-trained [10] [11]. The differential reflects volume efficiency, lower administrative overhead, and the absence of the layered insurance and rebate intermediaries that consume one-quarter to one-third of American spending.
Sixth, the consequences of the American architecture fall most heavily on the working poor and the racial minorities whose access to employer-sponsored insurance is most fragile [8]. Roughly 30% of Black adults and 35% of Hispanic adults carry medical debt, versus 22% of white adults. The maternal mortality differential between Black and white American women is roughly 2.6 to 1 — wider than the equivalent gap in any peer country. The system that bankrupts the insured middle class also kills the uninsured poor at differential rates.
Every other wealthy democracy has constructed universal coverage. The United States has chosen not to. The mechanisms — Medicare, Medicaid, the marketplaces — exist to expand into a universal architecture if Congress chooses. The Inflation Reduction Act's drug price negotiation demonstrates that the legislative tools to compress prices exist [14]. What is absent is not the technical capability to reform the system but the political coalition to do so. International comparison removes the alibi that the current US arrangement is medically inevitable; it is a settlement among interests, and settlements can be renegotiated.
Seventh, the universal systems are not without problems. The NHS funding crisis is real, the Canadian wait-list mortality is real, and the Indian out-of-pocket impoverishment is real [6] [7] [15]. Yet each pathology has a structural diagnosis and a structural remedy. The NHS needs higher funding; the Canadian system needs faster elective throughput; the Indian system needs deeper insurance penetration. Each problem is tractable. None of the pathologies of peer systems approaches the scale of the American excess: $14,885 per capita producing 78.4-year life expectancy, with 100 million Americans carrying medical debt.
The reader returning to the question that titles this report — what does a benchmark dollar amount buy in healthcare — finds an unstable answer. In Paris that amount covers a year of supplementary insurance. In Bangkok it underwrites a full cardiac workup. In Mumbai it pays for a substantial elective surgery. In New York it covers a single emergency-room visit. The variation is not medical. It is political.
Each health system signals through its prices what — and whom — it has been designed to serve. The American system has been optimised for revenue generation among specialists, pharmaceutical manufacturers, and billing intermediaries; its outcomes for the patient reflect that priority. The French and Japanese systems have been optimised for population health and have, by every comparative measure that matters, delivered it. The British system was optimised for population health and is now being asked, by chronic underfunding, to do so under increasingly impossible conditions. The Indian system is in the middle of a tractable transition toward broader coverage and faces a measurable distance still to travel. What the eight systems collectively demonstrate is that healthcare arrangements are choices, not natural facts. The choice the United States has made is the most expensive and least successful of any wealthy democracy. The choice can be remade. The comparison is the case.